In healthy volunteers, an intravenous DMT bolus produced very fast and brief effects: peak subjective intensity typically emerged within 1 to 3 minutes and declined quickly, with noticeable effects lasting about 12 to 30 minutes depending on dose. Plasma levels peaked around 2 to 3 minutes and fell rapidly, mirroring the time course.
Across 5 to 20 mg, intensity rose with dose, but a practical ceiling for peak intensity appeared from about 15 mg. Higher doses mainly prolonged the experience and increased unpleasant reactions rather than boosting the peak. No clear acute tolerance was seen across repeated boluses spaced by about an hour.
Context strongly shaped how the bolus felt. When doses were predictable and escalated stepwise in an open-label setup, negative effects were markedly lower than in a double-blind, randomized order. Expectation, control, and predictability reduced fear and distress, highlighting the impact of set and setting.
These results come from healthy participants in a controlled lab and do not test therapeutic efficacy. Still, they suggest that titration and clear expectations can improve tolerability more than pushing beyond ~15 mg for a higher peak. For full details, see the Translational Psychiatry report here: dose and context shape acute IV DMT effects.
Bottom line: dose sets the intensity window, but context shapes how tolerable that window feels.